Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
This article has no abstract
Epistemonikos ID: 4a31574e8d344e3863d8d11aaca76258a4237790
First added on: Apr 17, 2025